Lupin's IPMG is responsible for creating, securing, and leveraging a portfolio of high-value patents, products, and research pipeline projects. IPMG has also successfully managed patent challenges in courts and patent offices around the world.
In FY2018, the company was first-to-file with respect to generic versions of Nascobal® Nasal Spray, Triumeq® Tablets, Trintellix® Tablets, Bromsite® Ophthalmic Solution, Aptiom® Tablets, Farxiga® Tablets, Xigduo XR® Tablets, and Qtern® Tablets.
Cumulative ANDA and NDA filings with U.S. FDA now stand at 402, with 239 approvals as of FY2018. Lupin has a total of 36 first-to-file ANDAs pending launch, which includes 15 exclusive first-to-file opportunities.
In FY2018, the company settled a number of pending patent litigations on favorable terms and prevailed in litigations involving generic versions of Vivlodex®, Effient®, Namenda XR®, Locoid® and Axiron®.
Our research led patent filings were strong as we ﬁled 208 patent applications in FY2018. Since its inception, Lupin has filed 3,045 patent applications worldwide. The patent applications ﬁled in this financial year include 32 formulation patent applications, 75 API patent applications, 21 biotech patent applications, and 80 NDDD patent applications. We successfully secured 63 patents in FY18, including 34 NDDD patents.